PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH CISPLATIN (CDDP) ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Takahashi, S.
Ura, T. [1 ]
Nakano, K.
Chin, K.
Yokoyama, M.
Hatake, K.
Yokota, T. [1 ]
Shitara, K. [1 ]
Muro, K. [1 ]
Aoyama, T.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies
    Fishman, MN
    Garrett, CR
    Simon, GR
    Chiappori, AA
    Lush, RM
    Dinwoodie, WR
    Mahany, JJ
    Dellaportas, AM
    Cantor, A
    Gollerki, A
    Cohen, MB
    Sullivan, DM
    CLINICAL CANCER RESEARCH, 2006, 12 (02) : 523 - 528
  • [32] Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors
    Sausville, E. A.
    Garbo, L. E.
    Weiss, G. J.
    Shkolny, D.
    Yurkovetskiy, A. V.
    Bethune, C.
    Ramanathan, R. K.
    Fram, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors
    Ong, Michael
    Del Conte, Gianluca
    Bahleda, Rastislav
    Mateo, Joaquin
    Damian, Silvia
    Perotti, Antonella
    Lassau, Nathalie
    Farace, Franoise
    Lovosgaldeano, Jimena
    Tunariu, Nina
    Hospitel, Marie
    Mariani, Paola
    Cohen, Patrick
    Capri, Giuseppe
    Soria, Jean-Charles
    Gianni, Luca
    Molife, L. Rhoda
    Sessa, Cristiana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors
    Vokes, EE
    Goh, BC
    Bertucci, D
    Vogelzang, NJ
    Mani, S
    Ratain, MJ
    CANCER, 1999, 86 (03) : 528 - 532
  • [35] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors
    Nithya Ramnath
    Gary N. Schwartz
    Patrick Smith
    Daniel Bong
    Peter Kanter
    Joanne Berdzik
    Patrick J. Creaven
    Cancer Chemotherapy and Pharmacology, 2003, 51 : 227 - 230
  • [36] Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors
    Ramnath, N
    Schwartz, GN
    Smith, P
    Bong, D
    Kanter, P
    Berdzik, J
    Creaven, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (03) : 227 - 230
  • [37] PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTERED DAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS
    CATIMEL, G
    CHABOT, GG
    GUASTALLA, JP
    DUMORTIER, A
    COTE, C
    ENGEL, C
    GOUYETTE, A
    MATHIEUBOUE, A
    MAHJOUBI, M
    CLAVEL, M
    ANNALS OF ONCOLOGY, 1995, 6 (02) : 133 - 140
  • [38] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Metaxas, Yannis
    Kahatt, Carmen
    Alfaro, Vicente
    Fudio, Salvador
    Zeaiter, Ali
    Plummer, Ruth
    Sessa, Cristiana
    Von Moos, Roger
    Forster, Martin
    Stathis, Anastasios
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 91 - 98
  • [39] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Yannis Metaxas
    Carmen Kahatt
    Vicente Alfaro
    Salvador Fudio
    Ali Zeaiter
    Ruth Plummer
    Cristiana Sessa
    Roger Von Moos
    Martin Forster
    Anastasios Stathis
    Investigational New Drugs, 2022, 40 : 91 - 98
  • [40] Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
    Rothenberg, ML
    Sharma, A
    Weiss, GR
    Villalona-Calero, MA
    Eckardt, JR
    Aylesworth, C
    Kraynak, MA
    Rinaldi, DA
    Rodriguez, GI
    Burris, HA
    Eckhardt, SG
    Stephens, CD
    Forral, K
    Nicol, SJ
    Von Hoff', DD
    ANNALS OF ONCOLOGY, 1998, 9 (07) : 733 - 738
12345